Placebo (B)

OTHER4 trials

Sponsors

SciNeuro, Inipharm Australia Pty Ltd, S-INFINITY Pharmaceuticals Co., Ltd, FH Joanneum Gesellschaft mbH

Conditions

Alzheimer's DiseaseCircadian Rhythm DisordersGut Microbiota ModulationHealthyMetabolic Dysfunction-Associated SteatohepatitisNeurodegenerative DiseasesObesity & OverweightPrediabetes (Insulin Resistance, Impaired Glucose Tolerance)

Phase 1

A First Time in Human Study of SNP318 as a Treatment for Neurodegenerative Diseases Including Alzheimer's Disease

CompletedNCT05792163

SciNeuroAlzheimer's Disease, Neurodegenerative Diseases

Start: 2023-03-20End: 2023-11-29Updated: 2023-12-15

A Phase 1 Study of XH-S003 in Healthy Volunteers

CompletedNCT05946876

S-INFINITY Pharmaceuticals Co., LtdHealthy

Start: 2023-08-24End: 2024-08-14Updated: 2024-11-19

A Study of INI-822 in Healthy Volunteers and Participants With Metabolic Dysfunction-Associated Steatohepatitis (MASH) or Presumed MASH

RecruitingNCT05945537

Inipharm Australia Pty LtdMetabolic Dysfunction-Associated Steatohepatitis

Start: 2023-09-08End: 2026-10-31Target: 168Updated: 2026-08-03

Unknown Phase

Effects of Akkermansia Muciniphila and Berberine Supplementation on Insulin Sensitivity in Night-shift Workers

RecruitingNCT07440147

FH Joanneum Gesellschaft mbHCircadian Rhythm Disorders, Gut Microbiota Modulation, Obesity & Overweight +1

Start: 2026-01-20End: 2028-02-01Target: 200Updated: 2026-02-27